PubMed

Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.

Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH.

Diabetes Care. 2003 Jun;26(6):1796-801.PMID: 12766112 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.PMID: 16780391 [PubMed - indexed for MEDLINE]Related articles

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.PMID: 12648031 [PubMed - indexed for MEDLINE]Related articles

A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.

Wilson K, Marriott J, Fuller S, Lacey L, Gillen D.

Pharmacoeconomics. 2003;21 Suppl 1:1-11.PMID: 12648030 [PubMed - indexed for MEDLINE]Related articles

A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.

Maclaine GD, Patel H.

Int J Clin Pract. 2001 May;55(4):243-9.PMID: 11406909 [PubMed - indexed for MEDLINE]Related articles

Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.

Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.

Clin Ther. 1999 Nov;21(11):1924-36.PMID: 10890264 [PubMed - indexed for MEDLINE]Related articles

Effective use of statins to prevent coronary heart disease.

Crouch MA.

Am Fam Physician. 2001 Jan 15;63(2):309-20, 323-4. Review.PMID: 11201696 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.PMID: 10819699 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.PMID: 18047388 [PubMed - indexed for MEDLINE]Related articles

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.PMID: 11900720 [PubMed - indexed for MEDLINE]Related articles

Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.

Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.

Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94.PMID: 17996658 [PubMed - indexed for MEDLINE]Related articles

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.

Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J.

Mayo Clin Proc. 2005 May;80(5):587-95.PMID: 15887425 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of HMG-CoA reductase inhibition in Canada.

Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.

Can J Clin Pharmacol. 2001 Spring;8(1):9-16.PMID: 11283756 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.PMID: 18691996 [PubMed - indexed for MEDLINE]Related articles

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76.PMID: 18345946 [PubMed - indexed for MEDLINE]Related articles

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.

Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.

Pharmacoeconomics. 2008;26(4):329-39.PMID: 18370567 [PubMed - indexed for MEDLINE]Related articles

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.PMID: 19221376 [PubMed - indexed for MEDLINE]Related articlesFree article

Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.

Hilleman DE, Wurdeman RL, Lenz TL.

Pharmacotherapy. 2001 Apr;21(4):410-5.PMID: 11310513 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of statins.

Huse DM, Russell MW, Miller JD, Kraemer DF, D'Agostino RB, Ellison RC, Hartz SC.

Am J Cardiol. 1998 Dec 1;82(11):1357-63.PMID: 9856919 [PubMed - indexed for MEDLINE]Related articles

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.

Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S.

Clin Ther. 2007 Mar;29(3):519-28.PMID: 17577472 [PubMed - indexed for MEDLINE]Related articles